Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1915 results about "Pyran" patented technology

In chemistry, pyran, or oxine, is a six-membered heterocyclic, non-aromatic ring, consisting of five carbon atoms and one oxygen atom and containing two double bonds. The molecular formula is C₅H₆O. There are two isomers of pyran that differ by the location of the double bonds. In 2H-pyran, the saturated carbon is at position 2, whereas, in 4H-pyran, the saturated carbon is at position 4.

Photochromic compounds

Various non-limiting embodiments disclosed herein relate generally to photochromic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. Other non-limiting embodiments relate to photochromic-dichroic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. For example, one non-limiting embodiment provides a thermally reversible, photochromic compound adapted to have at least a first state and a second state, wherein the thermally reversible, photochromic compound has an average absorption ratio greater than 2.3 in at least one state as determined according to CELL METHOD. Another non-limiting embodiment provides a photochromic compound comprising: (a) at least one photochromic group chosen from a pyran, an oxazine, and a fulgide; and (b) at least one lengthening agent L attached to the at least one photochromic group and represented by the formula —[S1]c-[Q1-[S2]d]d′-[Q2-[S3]e]e′-[Q3-[S4]f]f′—S5—P, which is described herein.
Owner:TRANSITIONS OPTICAL INC

Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments

The invention relates to a crystalline hydrate of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and to crystalline complexes between 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and a natural amino acid, to methods for the preparation thereof, as well as to uses thereof for preparing medicaments.
Owner:BOEHRINGER INGELHEIM INT GMBH

Propiophenone derivatives and process for preparing the same

A propiophenone derivative of the formula (I): wherein OX is a hydroxy group which may optionally be protected, Y is a lower alkyl group, and Z is a beta -D-glucopyranosyl group wherein one or more hydroxy groups may optionally be protected, or a pharmaceutically acceptable salt thereof. Said compounds have excellent hypoglycemic activity so that they are useful in the prophylaxis or treatment of diabetes.
Owner:MITSUBISHI TANABE PHARMA CORP

Photochromic materials demonstrating improved fade rates

Various photochromic materials are provided that are essentially free of polymerizable unsaturated groups, and comprise: a) an indeno[2′,3′:3,4]naphtho[1,2-b]pyran; and b) an electron-withdrawing, non-conjugating group bonded at the 11-position of the indeno[2′,3′:3,4]naphtho[1,2-b]pyran. Alternative embodiments include various substituents at other positions of the indeno[2′,3′:3,4]naphtho[1,2-b]pyran. Also provided are photochromic articles including a substrate and one of the above photochromic materials, in contact with at least a portion of the substrate.
Owner:TRANSITIONS OPTICAL INC +1

Diaryl-2H-naphthopyrans

Photochromic diaryl-2H-naphthopyran structures, which dye photochromically well at room temperature, lighten up quickly when incorporated into ophthalmic lenses, possess longevity, and due to their spacial structures, have a reduced tendency of the molecules to migrate in plastics.
Owner:OPTISCHE WERKE G RODENSTOCK

Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6) alkyl, -(C2-C6) alkenyl, or -(C2-C6) alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is -O-; -S(=O)t-, where t is 0, 1, or 2; or -N(R3)-; Y is =C(R1a)-, or -[N<custom-character file="US20020111495A1-20020815-P00900.TIF" wi="20" he="20" id="custom-character-00001" / >(O)k] where k is 0 or 1; R4, R5 and R6 are (1) -H; provided that R5 and R6 are not both -H at the same time, -F; -Cl; -(C2-C4) alkynyl; -R16; -OR16; -S(=O)pR16; -C(=O)R16, -C(=O)OR16, -C(=O)OR<highlight><sup
Owner:PFIZER INC

Photochromic naphthopyran compounds: compositions and articles containing those naphthopyran compounds

InactiveUS7008568B2High sensitivity to solar radiationEliminate needOrganic chemistryDiffusing elementsCompound aSulfur
A photochromic naphthopyran displays good color distribution when the naphthopyran has a central nucleus of the formula: wherein F is a 5-member, 6-member, or 7-member heterocyclic ring group having only one heteroatom, the heteroatom selected from the group consisting of oxygen, sulfur, and nitrogen, the 2,3 or 3,2 positions of the heterocyclic ring fused to the g, h, or i side;R1 and R2 are the atoms or groups providing photochromic properties to the naphthopyran.
Owner:HOYA OPTICAL LABS OF AMERICA INC

Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof

InactiveUS6617313B1BiocideSaccharide with heterocyclic radicalsD-GlucopyranosePterocarpus marsupium
A novel glucopyranoside, 2,6-dihydroxy-2-(P-hydroxybenzyl)-3(2H) benzofuran-7-C-beta-D-glucopyranoside of the formula 1isolated from Pterocarpus marsupium and to a process for the isolation thereof is disclosed. The invention also relates to a pharmaceutical composition containing 2,6-dihydroxy-2-(P-hydroxybenzyl)-3(2H)benzofuran-7-C-beta-D-glucopyranoside and to method for the treatment of diabetes using said compound.
Owner:COUNCIL OF SCI & IND RES

Salts and crystalline forms of an apoptosis-inducing agent

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Owner:ABBVIE INC

Tissue degeneration protection

The present invention provides isolated or essentially pure diterpenoic tetrahydropyran, such as steviol-19-glucuronide, steviol, stevioside and rebaudioside processes for obtaining the same and methods for obtaining stable pharmaceutically acceptable salts of the same for use of such compounds or compositions in a treatment of cardiovascular disorders or vascular disease or for the manufacture of medicaments to treat a condition of a cardiovascular disorder or vascular disease.
Owner:GEUNS JOANNES +1

Alkenyl compound having a negative delta epsilon value, liquid crystal composition, and liquid crystal display device

There are provided a liquid crystalline compound having a large negative Deltaepsilon, low viscosity, a large K33 / K11 value, a small Deltaepsilon / epsilonL and mutually excellent solubility even at extremely low temperature; a liquid crystal composition prepared from a liquid crystalline compound; and a liquid crystal display device fabricated from such a liquid crystal composition. The liquid crystalline compound of the present invention is a liquid crystalline compound represented by the following general formula (1): where, R<1 >represents hydrogen, fluorine, an alkyl group having 1 to 15 carbon atoms, or an alkenyl group having 2 to 15 carbon atoms; each of rings A<1>, A<2>, and A<3 >independently represents trans-1,4-cyclohexylene group, 1,4-cyclohexenylene group, trans-1,4-silacyclohexylene group, 1,4-phenylenegroup, 2,3-difluoro-1,4-phenylene group, 2-fluoro-1,4-phenylene group, 3-fluoro-1,4-phenylene group, pyrimidine-2,5-diyl group, pyridine-2,5-diyl group, 1,3-dioxane-2,5-diyl group, tetrahydropyrane-2,5-diyl group, 1,3-dithiane-2,5-diyl group, or tetrahydrothiopyrane-2,5-diyl group; X<1 >represents hydrogen or fluorine; Y<1 >represents hydrogen or an alkyl group having 1 to 15 carbon atoms; 1 represents an integer from 1 to 10; and each of m and n independently represents 0 or 1.
Owner:JNC CORP

Photochromic compounds and compositions

Described herein are compounds generally comprising an indeno[2′,3′:3,4]naptho[1,2-b]pyran structure. Such compounds may be useful for their photochromic properties, and be used in certain photochromic compositions. Such compositions may further comprise other photochromic compositions and / or materials. Additionally, such compounds and / or compositions may be suitable for preparing certain photochromic articles. Also described herein are methods for preparing certain photochromic compounds, compositions, and articles.
Owner:TRANSITIONS OPTICAL INC

17-hydroxy c27 steroid compound and its synthesis and use

The present invention is one kind of 17-hydroxy C27 steroid compound and its synthesis and use. The synthesis process of the present invention is simple and suitable for industrial production in synthesizing pennogenin as well as dihydro pennogenin and OSW-1 aglycone analog.
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI

Hydroxy piperidine derivatives to treat gaucher disease

The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. The linker can be absent if the lipophilic moiety corresponds to a hydrocarbon chain with a linear length of 6 or more carbons. The present invention further provides a method for treating individuals having Gaucher disease by administering the novel HP derivative as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease.
Owner:AMICUS THERAPEUTICS INC

Photochromic materials comprising metallocenyl groups

Various non-limiting embodiments of the present invention relate to photochromic materials having a metallocenyl group. More particularly, various non-limiting embodiments disclosed herein provide photochromic materials including an indeno-fused naphthopyran, such as an indeno[2′,3′:3,4]naphtho[1,2-b]pyran, and a metallocenyl group bonded to at least one available position on the indeno-fused naphthopyran. Other non-limiting embodiments disclosed herein provide photochromic composition and photochromic articles, such as but not limited to ophthalmic lens, which include the disclosed photochromic materials and method of making the same.
Owner:TRANSITIONS OPTICAL INC

Photoresist polymeric compound and photoresist resin composition

A polymeric compound of the invention includes at least one monomer unit selected from the following formulae (I), (II), (III) and (IV):(wherein R<1 >is a hydrogen atom or a methyl group, R<2 >and R<3 >are each a hydrogen atom, a hydroxyl group or a -COOR<4 >group, where R<4 >is, e.g., a t-butyl group or a 2-tetrahydropyranyl group; R<5 >and R<6 >are each a hydrogen atom, a hydroxyl group or an oxo group; R<7>, R<8 >and R<9 >are each a hydrogen atom or a methyl group; R<10 >and R<11 >are each a hydrocarbon group having 1 to 8 carbon atoms; R<12>, R<13 >and R<14 >are each a hydrogen atom, a hydroxyl group or a methyl group, where if all of R<12 >to R<14 >are each a hydrogen atom or a hydroxyl group, R<10 >and R<11 >are not coincidentally methyl groups) [wherein, when the compound includes, for example, a monomer unit of Formula (III), the compound further includes at least one monomer unit selected from among, for example, a monomer unit represented by the following Formula (V):(wherein R<15 >and R<16 >are each a hydrogen atom, a hydroxyl group or a carboxyl group; R<17 >is a hydroxyl group, an oxo group or a carboxyl group; and R<1 >has the same meaning as defined above)]. This polymeric compound has high etching resistance, as well as satisfactory transparency, alkali-solubility and adhesion, and is therefore useful as a photoresist resin.
Owner:DAICEL CHEM IND LTD

Novel benzopyran derivatives as potassium channel openers

The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.
Owner:JANSSEN PHARMA NV

Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds

A pharmaceutical compositions comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof: wherein R1═R2 ═H; or R1 and R2 together form a moiety represented by the formula R3 represents a substituted or unsubstituted alkyl having 4-30 carbon atoms, or a substituted or unsubstituted aryl group having 3-30 carbon atoms; and R4 represents a substituted or unsubstituted aryl group having 3-30 carbon atoms; with the proviso that R3 is not butyl, pentyl, tetrahydropyranyloxymethyl, tetrahydropyranyloxypropyl or phenyl when R1═R2═H and R4 is o-cyanophenyl,; and with the proviso that R3 is not butyl when R1═R2═H and R4 is phenyl. The pharmaceutical composition may be used to treat a subject afflicted with a tumor / cancer by inhibiting topoisomerase I activities or blocking the S phase or G2 / M phase of the tumor / cancer cells.
Owner:KAOHSIUNG MEDICAL UNIVERSITY

Phenanthrene and imidazole-coumarin double-fluorescent group ratio fluorescent molecular probe for iron ion detection and synthesis and use methods thereof

The invention provides a phenanthrene and imidazole-coumarin double-fluorescent group ratio fluorescent molecular probe for iron ion detection and synthesis and use methods thereof, relates to fluorescent molecular probes and synthesis and application thereof and aims to solve the problem that an existing Fe<3+> fluorescent probe is prone to being interfered by pH, concentration and other metal ions. The fluorescent molecular probe is 4-methyl-7-hydroxide radical-8-[2-(1- phenyl group-1H-phenanthrene and [9, 10-d] imidazole-2-)benzene ammonia methylene]-2H-pyran-2-ketone. The phenanthrene and imidazole-coumarin double-fluorescent group ratio fluorescent molecular probe is formed by conducting condensation on 1-N-phenyl group-2-(2-aminophenyl)-1H-phenanthrene and [9, 10-d] imidazole and 4-methyl-7-hydroxide radical-8- formyl group coumarin, and the yield is 75-85%. The fluorescent molecular probe is dissolved in mixed liquid of N, N- dimethylformamide and an HEPES buffering solution, existence of iron ions is judged through the absorbance value or fluorescence intensity change before and after adding of test samples, and the fluorescent molecular probe can be used for detection of Fe<3+> pollution in water.
Owner:QIQIHAR UNIVERSITY

Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

The present invention is directed to novel substituted aminotetrahydropyrans of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Owner:SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products